ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,836.22
0.16%
US Tech 100
20,384.40
0.80%
Dow Jones
42,297.12
0.86%
Brent Oil
80.425
0.18%
Bitcoin
97,248.12
2.90%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Genelux Corporation (GNLX) Quote

Genelux Corporation

Genelux Corporation (GNLX)

NASDAQ
2.44
-0.14
(-5.43%)
Closed January 13 4:00PM
Delayed by 15 minutes
2.44
0.00
( 0.00% )
Pre Market: 4:05AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
2.44
Bid
2.33
Ask
2.62
Volume
-
0.00 Day's Range 0.00
1.60 52 Week Range 13.97
Market Cap
84.273M
Previous Close
2.44
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
147,273
Shares Outstanding
34,538,185
Dividend Yield
-
PE Ratio
-2.98
Earnings Per Share (EPS)
-0.82
Revenue
170k
Net Profit
-28.3M

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.genelux.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Genelux Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GNLX. The last closing price for Genelux was $2.44. Over the last year, Genelux shares have traded in a share price range of $ 1.60 to $ 13.97.

Genelux currently has 34,538,185 shares outstanding. The market capitalization of Genelux is $84.27 million. Genelux has a price to earnings ratio (PE ratio) of -2.98.

Ask ADVFN Intelligence (AI)

GNLX Latest News

More News

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

December 31 2024
Edgar (US Regulatory)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

December 31 2024
Edgar (US Regulatory)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

December 31 2024
Edgar (US Regulatory)

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

December 31 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 30 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

December 30 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 20 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.16-6.153846153852.62.762.3841879042.58794157CS
40.083.389830508472.362.762.13843552.43530702CS
12-0.23-8.614232209742.673.52.131472732.67594784CS
260.072.953586497892.373.61.61461752.52650547CS
52-10.51-81.158301158312.9513.971.61709373.59539856CS
156-3.56-59.3333333333640.981.615098211.03800638CS
260-3.56-59.3333333333640.981.615098211.03800638CS

GNLX - Frequently Asked Questions (FAQ)

What is the current Genelux share price?
The current share price of Genelux is $ 2.44
How many Genelux shares are in issue?
Genelux has 34,538,185 shares in issue
What is the market cap of Genelux?
The market capitalisation of Genelux is USD 84.27M
What is the 1 year trading range for Genelux share price?
Genelux has traded in the range of $ 1.60 to $ 13.97 during the past year
What is the PE ratio of Genelux?
The price to earnings ratio of Genelux is -2.98
What is the cash to sales ratio of Genelux?
The cash to sales ratio of Genelux is 497.96
What is the reporting currency for Genelux?
Genelux reports financial results in USD
What is the latest annual turnover for Genelux?
The latest annual turnover of Genelux is USD 170k
What is the latest annual profit for Genelux?
The latest annual profit of Genelux is USD -28.3M
What is the registered address of Genelux?
The registered address for Genelux is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Genelux website address?
The website address for Genelux is www.genelux.com
Which industry sector does Genelux operate in?
Genelux operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STAFStaffing 360 Solutions Inc
$ 4.55
(100.00%)
4.55M
PIIIP3 Partners Inc
$ 0.3552
(65.29%)
16.98M
ADDColor Star Technology Company Ltd
$ 2.56
(39.89%)
1.67M
LGCBLinkage Global Inc
$ 0.50
(28.87%)
2
GXAIGaxos ai Inc
$ 2.15
(28.74%)
1.18M
BCOW1895 Bancorp of Wisconsin Inc
$ 7.51
(-24.45%)
2
SVMHSRIVARU Holding Ltd
$ 0.0267
(-23.93%)
4.09M
AEHRAehr Test Systems
$ 12.34
(-22.83%)
84.03k
CTRNCiti Trends Inc
$ 20.51
(-21.99%)
1
PHIOPhio Pharmaceuticals Corporation
$ 5.16
(-21.82%)
246.9k
PIIIP3 Partners Inc
$ 0.3552
(65.29%)
16.98M
LAESSEALSQ Corporation
$ 3.86
(15.22%)
7.61M
GCTKGlucoTrack Inc
$ 0.1277
(-14.70%)
5.26M
STAFStaffing 360 Solutions Inc
$ 4.55
(100.00%)
4.55M
SVMHSRIVARU Holding Ltd
$ 0.0267
(-23.93%)
4.09M

GNLX Discussion

View Posts
stocktowatch stocktowatch 1 month ago
$GNLX Genelux_Corp Corporation to Participate in a Fireside Chat with H.C. Wainwright
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.



https://finance.yahoo.com/news/genelux-corporation-participate-fireside-chat-120100563.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
👍️0
stocktowatch stocktowatch 1 month ago
$GNLX November 2024 Corporate Presentation

https://investors.genelux.com/static-files/cb26a67f-274b-49ab-84cc-de52b67c4118
👍️0
stocktowatch stocktowatch 1 month ago
$GNLX NASDAQ Genelux 2024 Annual Stockholder Meeting


👍️0
TheFinalCD TheFinalCD 3 months ago
https://finviz.com/quote.ashx?t=GNLX&ty=c&ta=1&p=d
👍️0
stocksrising stocksrising 3 months ago
Any news for pop??
Found it….sorry, just saw


Genelux Corporation Announces
First Patient Dosed in Phase 2
Trial Evaluating Systemic
Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
GlobeNewswire
- VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-
doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent non-small cell lung cancer-
- Trial represents second indication in the clinic for Olvi-Vec via systemic administration -
- Interim readout expected mid-2025 -
WESTLAKE VILLAGE, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) - Genelux Corporation (GNLX. NaE) , a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer (NSCLC) who have failed frontline platinum and immune checkpoint inhibitor (ICI) therapies.
👍️0
stocktowatch stocktowatch 3 months ago
$GNLX Trending up resistance in play https://schrts.co/nQTnXUut
👍️ 1 💥 1
stocktowatch stocktowatch 3 months ago
$GNLX On alert for News!? stay tuned..
👍️0
stocktowatch stocktowatch 4 months ago
$GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

https://finance.yahoo.com/news/genelux-corporation-present-h-c-200100800.html
👍️0
stocktowatch stocktowatch 4 months ago
$GNLX 1 Month chart resistance in play https://schrts.co/BWBNmgEe
👍️0
stocktowatch stocktowatch 4 months ago
$GNLX Fundamental breakout Volume recovery get in early for the big boom https://schrts.co/sGWIJqyY
👍️0
Monksdream Monksdream 4 months ago
GNLX under $3
👍️0
stocktowatch stocktowatch 5 months ago
Is Genelux (NASDAQ: $GNLX) In A Good Position To Invest In Growth? https://finance.yahoo.com/news/genelux-nasdaq-gnlx-good-position-134334395.html
👍️0
stocktowatch stocktowatch 5 months ago
$GNLX Technical chart
https://schrts.co/SjVYghqR
👍️0
stocktowatch stocktowatch 6 months ago
$GNLX Website : https://genelux.com/
👍️0
Monksdream Monksdream 6 months ago
GNLX under $3
👍️0
stocktowatch stocktowatch 6 months ago
$GNLX historical movement price and volume https://ih.advfn.com/stock-market/NASDAQ/genelux-GNLX/historical
👍️0
Monksdream Monksdream 7 months ago
GNLX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
GNLX new 52 lo
👍️0
Monksdream Monksdream 9 months ago
GNLX new 52 lo
👍️0
MiamiGent MiamiGent 1 year ago
GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor

https://stockcharts.com/h-sc/ui?s=GNLX

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.

The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.
👍️0

Your Recent History

NASDAQ
GNLX
Genelux
USOTC
FKCIF
Fukui Computer (PK)
LSE
0J7G
Hutchison China Meditech
TG
GGD
GoGold Resources
USOTC
BIGG
Big Tree (CE)
USOTC
WPNTF
Warpaint London (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads